Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/27/2015 07/28/2015 07/29/2015 07/30/2015 07/31/2015 Date
11.03(c) 11.14(c) 11.14(c) 12.07(c) 12.24(c) Last
703 363 579 924 910 888 1 766 978 1 237 001 Volume
-0.18% +1.00% 0.00% +8.35% +1.41% Change
More quotes
Financials ($)
Sales 2015 110 M
EBIT 2015 -39,2 M
Net income 2015 -41,7 M
Debt 2015 -
Yield 2015 -
Sales 2016 151 M
EBIT 2016 -17,9 M
Net income 2016 -25,0 M
Debt 2016 -
Yield 2016 -
PER 2015 -
PER 2016
Capi. / Sales 2015 4,65x
Capi. / Sales 2016 3,38x
Capitalization 512 M
More Financials
Company
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.Its product portfolio includes Fanapt and Tasimelteon.The Fanapt product is a compound for the treatment of schizophrenia, the... 
More about the company
Surperformance© ratings of Vanda Pharmaceuticals Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on VANDA PHARMACEUTICALS INC.
07/31 VANDA PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condit..
07/29 VANDA PHARMACEUTICALS : reports 2Q loss
07/29 VANDA PHARMACEUTICALS : Results of Operations and Financial Condition, Financial..
07/29 VANDA PHARMACEUTICALS : Reports Second Quarter 2015 Financial Results
07/17 VANDA PHARMACEUTICALS : HETLIOZ Secures EC Approval for the Treatment of Non-24-..
07/15 VANDA PHARMACEUTICALS : to Announce Second Quarter 2015 Financial Results on Jul..
07/10 VANDA PHARMACEUTICALS : HETLIOZ Gets EC Approval for the Treatment of Non-24-Hou..
07/09 VANDA PHARMACEUTICALS : to Announce Second Quarter 2015 Financial Results on Jul..
More news
Sector news : Bio Therapeutic Drugs
07/31 QUINTILES TRANSNATIONAL : Announces Pricing of Secondary Public Offering
07/30 SEATTLE GENETICS : reports 2Q loss
07/30 QUINTILES TRANSNATIONAL : Announces Launch of Secondary Public Offering of Commo..
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
07/31 PREMARKET BIOTECH DIGEST : Amgen Beats, GlaxoSmithKline Corruption Charges, VTv ..
07/30 PREMARKET BIOTECH DIGEST : Familial Hypercholesterolemia, Dynavax BLA Track, Ear..
07/29 Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q2 2015 Results - ..
07/29 Vanda Pharmaceuticals beats by $0.16, beats on revenue
07/23 PREMARKET BIOTECH DIGEST : The M&A Frenzy, Anavex's Phase 2a Data, Big Day For E..


Comments 
Advertisement
Chart VANDA PHARMACEUTICALS INC.
Duration : Period :
Vanda Pharmaceuticals Inc. Technical Analysis Chart | VNDA | US9216591084 | 4-Traders
Full-screen chart
Technical analysis trends VANDA PHARMACEUTI...
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions